Pearl River Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pearl River Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,729	Closed	-$554K	–	52
2024 Q2	$554K	Buy	6,729 +2,851	+74%	+$237K	0.09%	265
2024 Q1	$339K	Buy	+3,878	New	+$347K	0.05%	371
2023 Q3	–	Sell	-9,579	Closed	-$830K	–	497
2023 Q2	$830K	Buy	+9,579	New	+$901K	0.13%	232
2023 Q1	–	Sell	-6,297	Closed	-$652K	–	502
2022 Q4	$652K	Sell	6,297 -19,026	-75%	-$1.79M	0.11%	279
2022 Q3	$2.15M	Buy	25,323 +12,228	+93%	+$1.09M	0.4%	69
2022 Q2	$1.08M	Sell	13,095 -6,866	-34%	-$547K	0.26%	129
2022 Q1	$1.54M	Buy	+19,961	New	+$1.67M	0.42%	68
2020 Q2	–	Sell	-1,527	Closed	-$129K	–	310
2020 Q1	$129K	Buy	+1,527	New	+$132K	0.25%	138
2019 Q1	–	Sell	-100	Closed	-$9K	–	396
2018 Q4	$9K	Buy	+100	New	+$9.51K	0.04%	590

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Pearl River Capital's BMRN Position: Q3 2024 in Review

Pearl River Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 6,729 shares — an estimated $554K sold.

Pearl River Capital first reported a position in BMRN in Q4 2018 and held it in 9 quarters. The position peaked at $2.15M in Q3 2022. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Pearl River Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Pearl River Capital sold 6,729 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $554K.
Pearl River Capital first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 9 quarters.
Pearl River Capital's BioMarin Pharmaceuticals position peaked at $2.15M in Q3 2022.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.